Oncology

28 years of oncology expertise transforming promising ideas into breakthrough therapies

In-vitro cytotoxicity testing, lead optimization and functional biology biomarker panels for anti-cancer drug development. 

2D Cancer Cells and Primary Cell Lines (3)-1

Targeted Cancer Screening and Preclinical Testing

Screen hundreds of compounds simultaneously against a diverse panel of 380+ human cancer cell lines. Access a library of 50+ approved cancer drugs to test compounds alone or in combination. Pair these studies with in vitro cytotoxicity assays to generate actionable data for early oncology drug development and compound prioritization.
Untitled design (20)-1-1
Compound Screening
Multi-Cell Line Testing
Cytotoxicity Analysis
Actionable Data
Screenshot 2026-02-03 at 10.15.16 AM

TEST FASTER. COMPARE EASIER. DISCOVER MORE. Compare, Combine and Validate Against 50+ Proven Cancer Drugs

Access a curated panel of approved and investigational oncology drugs for immediate comparison and combination studies, alongside testing across 380 human cancer cell lines. 

Lead Drug Optimization and Peptide Therapeutics Development Capabilites

  • Cyclization
  • Biotinylation
  • Phosphorylation
  • Glycosylation
  • Binding of specific small MW toxic-drugs
  • Non-radioactive Cytotoxicity Assays (Multi-Tox Glo & ApoGlow
ChatGPT Image Feb 3, 2026, 01_19_35 PM-1

Cancer Drugs Available for Research Purposes

Oncology Biomarker Panels Designed for Early Drug Development

Apoptosis and Epithelial Tumors

Biomarker

Cancer 

Role

Cleaved Cytokeratin 18 (M30)

Breast, colon, liver

Apoptotic epithelial cell marker

Cytokeratin 18 (total)

Breast, colon, liver

Total epithelial cell death

Caspase 3/7 Activity

Broad solid tumors

Apoptotic pathway activation

High Mobility Group Box 1 (HMGB1)

Various solid tumors

Marker of tumor cell death/necrosis

Galectin-3

Thyroid, breast, colorectal

Tumor progression and immune evasion

Angiogenesis and Tumor Growth

Biomarker

Cancer 

Notes

VEGF-A

Breast, colon, renal, lung

Key angiogenesis driver

VEGF-C

Breast, colorectal

Lymphangiogenesis

VEGF-D

Various solid tumors

Lymphatic metastasis potential

VEGFR1

Solid tumors

VEGF receptor; targetable

PDGF-AA/AB/BB

Glioblastoma, sarcoma, pancreatic

Tumor growth and stromal activation

FGF-basic

Breast, colon, melanoma

Angiogenesis

PIGF

Solid tumors

Tumor vascular remodeling

Tie-2

Tumor vasculature

Endothelial activation marker

Immuno-Oncology and Tumor Microenvironment

Biomarker

Cancer 

Notes

4-1BB (CD137)

Solid tumors, immunotherapy

T-cell co-stimulation, checkpoint target

Granzyme B

Broad solid tumors

Cytotoxic T-cell activity

Perforin

Solid tumors

T/NK cell-mediated tumor killing

Galectin-1

Glioblastoma, pancreatic

Tumor immune evasion

TNF-α

Various

Inflammatory marker, tumor progression

IL-6

Lymphoma, breast, prostate

Chronic inflammation, tumor-promoting

IL-8

Melanoma, ovarian, lung

Angiogenesis, metastasis

MCP-1 (CCL2)

Breast, prostate, ovarian

Tumor-associated macrophage recruitment

MIP-1β (CCL4)

Tumor microenvironment

Immune cell recruitment

TARC (CCL17)

Hodgkin lymphoma

Immune microenvironment

Inflammation and Tumor Progression

Biomarker

Cancer 

Notes

CRP

Various cancers

General inflammation

SAA

Breast, lung

Acute phase protein elevated in tumor progression

ICAM-1 / VCAM-1

Metastatic tumors

Endothelial activation, metastasis potential

TGF-β1

Breast, colon, pancreatic

Tumor progression, immune modulation

TGF-α

EGFR-driven tumors

Tumor proliferation

Galectin-1

Solid tumors

Immune evasion

Hematologic and Multiple Myeloma

Biomarker

Cancer 

Notes

Beta-2-Microglobulin

Multiple myeloma, lymphoma

Disease progression marker

Fms-Related Tyrosine Kinase 3 Ligand (Flt3L)

Leukemia

Hematopoietic growth, prognosis

IL-1β, IL-10, IL-12p70

Leukemia, lymphoma

Immune modulation

TNF-β

Lymphoma

Immune/inflammatory context

Biomarkers Organized by Cancer Type

While our functional biology–based oncology panels group biomarkers by pathway and mechanism of action, many programs are organized around specific tumor indications. To support indication-driven development strategies, we also provide a comprehensive listing of our oncology biomarkers organized by cancer type, making it easy to align panel selection with your therapeutic focus. 
Our Cancer Panels

From Discovery to IND: Oncology Solutions

ChatGPT Image Feb 6, 2026, 03_55_50 PM-1

Biomarkers

ChatGPT Image Feb 6, 2026, 03_55_50 PM-2-1

Bioassays

ChatGPT Image Feb 6, 2026, 03_55_50 PM-3-1

Cytokines

ChatGPT Image Feb 6, 2026, 03_55_50 PM-4

mAbs

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-06-47-8201-PM

Bioanalysis

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-07-33-6836-PM

Cell & Gene Therapy

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-08-15-7797-PM

Small Molecule

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-08-50-3909-PM

Antibody Development

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-10-52-1925-PM

Biosimilars

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-10-14-1794-PM

Molecular Diagnostics

High Impact Anti-Cancer Drug Screening

SBH Sciences is actively collaborating with Karyopharm Therapeutics on its anti-cancer development program. We have used over 200 cancer cell lines in this collaboration and are continuing to screen for promising anti-cancer drugs. SBH Sciences and Karyopharm Therapeutics have presented 10 scientific abstracts together.